Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix(TM) Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Business Wire March 4, 2021

Ocular Therapeutix(TM) Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

Business Wire March 1, 2021

Ocular Therapeutix(TM) To Report Fourth Quarter and Year End 2020 Financial Results

Business Wire February 25, 2021

Ocular Therapeutix(TM) to Participate at Three Upcoming Investor Conferences

Business Wire February 24, 2021

Ocular Therapeutix(TM) Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Business Wire February 12, 2021

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 4, 2021

Ocular Therapeutix(TM) Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum

Business Wire January 20, 2021

Ocular Therapeutix(TM) Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development

Business Wire January 7, 2021

Ocular TherapeutixTM Announces Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire December 28, 2020

Ocular Therapeutix(TM) Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Business Wire December 22, 2020

Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock

Business Wire December 15, 2020

Ocular Therapeutix(TM) Announces Proposed Public Offering of Common Stock

Business Wire December 14, 2020

Ocular Therapeutix(TM) to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Business Wire November 23, 2020

Ocular Therapeutix(TM) To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting

Business Wire November 11, 2020

Ocular Therapeutix(TM) to Participate at Two Upcoming Investor Conferences

Business Wire November 9, 2020

Ocular Therapeutix(TM) Reports Third Quarter 2020 Financial Results and Business Update

Business Wire November 5, 2020

Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

Business Wire November 4, 2020

Ocular Therapeutix(TM) and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia

Business Wire October 30, 2020

Ocular Therapeutix(TM) To Report Third Quarter 2020 Financial Results

Business Wire October 23, 2020

Ocular Therapeutix(TM) Announces Pricing of Public Offering of Common Stock

Business Wire October 14, 2020